A Phase I Single-Center, Randomized, Double-Blind, Placebo-Controlled, Combined Single Ascending Dose, Multiple Ascending Dose, and Food Effect Study to Investigate the Safety and Tolerability, Pharmacokinetics, and Pharmacodynamics of K-755 in Healthy Adult Volunteers
Phase of Trial: Phase I
Latest Information Update: 08 Mar 2018
At a glance
- Drugs K-755 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Kowa Pharmaceutical
- 01 Mar 2018 Planned End Date changed from 28 Feb 2018 to 27 Feb 2020.
- 01 Mar 2018 Planned primary completion date changed from 28 Feb 2018 to 27 Feb 2020.
- 01 Mar 2018 Status changed from not yet recruiting to recruiting.